EGM
NKTR icon

Engineers Gate Manager’s Nektar Therapeutics NKTR Stock Holding History

Engineers Gate Manager’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.34M Buy
19,183
+6,881
+56% +$503K 0.02% 914
2026
Q1 		$885K Sell
12,302
-24,982
-67% -$1.42M 0.01% 1112
2025
Q4 		$1.58M Buy
37,284
+19,654
+111% +$1.1M 0.02% 820
2025
Q3 		$1M Buy
+17,630
New +$584K 0.01% 1150
2024
Q4 		– Sell
-893
Closed -$17.4K – 2463
2024
Q3 		$17.4K Buy
+893
New +$17K ﹤0.01% 2037
2023
Q1 		– Sell
-1,374
Closed -$46.6K – 1889
2022
Q4 		$46.6K Buy
+1,374
New +$66.5K ﹤0.01% 1557
2022
Q3 		– Sell
-5,797
Closed -$330K – 1926
2022
Q2 		$330K Sell
5,797
-3,761
-39% -$237K 0.01% 1353
2022
Q1 		$773K Buy
9,558
+8,536
+835% +$1.26M 0.03% 817
2021
Q4 		$207K Buy
+1,022
New +$222K 0.01% 1638
2021
Q3 		– Sell
-8,607
Closed -$2.21M – 1859
2021
Q2 		$2.21M Buy
8,607
+6,678
+346% +$1.85M 0.14% 153
2021
Q1 		$579K Sell
1,929
-7,497
-80% -$2.33M 0.03% 902
2020
Q4 		$2.4M Buy
9,426
+7,133
+311% +$1.84M 0.1% 271
2020
Q3 		$571K Buy
2,293
+1,337
+140% +$421K 0.03% 915
2020
Q2 		$332K Sell
956
-1,646
-63% -$514K 0.02% 1169
2020
Q1 		$697K Buy
2,602
+1,455
+127% +$450K 0.05% 598
2019
Q4 		$371K Sell
1,147
-8,062
-88% -$2.34M 0.02% 1145
2019
Q3 		$2.52M Buy
9,209
+8,310
+924% +$3.05M 0.13% 241
2019
Q2 		$479K Sell
899
-230
-20% -$115K 0.03% 735
2019
Q1 		$569K Buy
+1,129
New +$669K 0.03% 584
2016
Q2 		– Sell
-2,846
Closed -$587K – 784
2016
Q1 		$587K Buy
+2,846
New +$547K 0.05% 462
2015
Q1 		– Sell
-904
Closed -$210K – 1022
2014
Q4 		$210K Buy
+904
New +$193K 0.06% 588

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Engineers Gate Manager's NKTR Position: Q2 2026 in Review

Engineers Gate Manager increased its Nektar Therapeutics (NKTR) stake by 56% in Q2 2026, buying an estimated $503K and bringing the position to 19,183 shares worth $1.34M. The position accounts for 0.02% of the portfolio, ranked #914.

Engineers Gate Manager first reported a position in NKTR in Q4 2014 and has held it in 21 quarters since. The position peaked at $2.52M in Q3 2019. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Engineers Gate Manager held 19,183 shares of Nektar Therapeutics worth $1.34M as of Q2 2026.
  • Engineers Gate Manager bought 6,881 Nektar Therapeutics shares in Q2 2026, an estimated $503K.
  • Nektar Therapeutics made up 0.02% of Engineers Gate Manager's portfolio in Q2 2026, its #914 holding.
  • Engineers Gate Manager first reported a position in Nektar Therapeutics in Q4 2014 and has held it in 21 quarters since.
  • Engineers Gate Manager's Nektar Therapeutics position peaked at $2.52M in Q3 2019.
  • 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Engineers Gate Manager's 13F filing for Q2 2026, filed 14 Aug 2026.